Osteoglycin (OGN) showed to be decreased within multiple malignancies, such as stomach cancer [8], cervical squamous carcinoma, vaginal cancer [9], colorectal adenoma [10], invasive ductal breast carcinoma [11], and laryngeal carcinoma [12]. This evidence concerns the gene OGN and gastric cancer.